ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

12 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

21 Mar 2022 16:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call

17 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

08 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

02 Feb 2022 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

25 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

10 Jan 2022 08:00:10 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 16:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

09 Dec 2021 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

11 Nov 2021 16:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

08 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 09:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

07 Oct 2021 08:55:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

30 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

21 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

01 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

16 Aug 2021 16:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

10 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

28 Jun 2021 08:00:00 By Nasdaq GlobeNewswire